InvestWiser

ChemoMetec A/S

CHEMMNasdaq CopenhagenHealthcareMarket value 11.9 bn DKK
694.50DKK +0.9%
last day · Price as of 18 November 2026

The answer first

Does ChemoMetec beat the market?

No, ChemoMetec has not beaten the market over the last year.

ChemoMetec−7.4%København (OMXCGI)+13.9%
  • The ranking · Quality, value and trend combined

    Better than 72% of Nordic stocks

    • Quality100
    • Value6
    • Trend81

    No. 35 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash ChemoMetec keeps must grow about 22% a year for 10 years.

Max for seven days

Follow ChemoMetec with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on ChemoMetec

From today, at a price of 694.50 DKK. Write why you follow ChemoMetec, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about ChemoMetec

Your first answer is free, no account needed.

Do you own ChemoMetec, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with ChemoMetec and a few more. Free, no card.

Past year against the exchange and Super Stock
ChemoMetec−7.4%København (OMXCGI)+13.9%Super Stock+44.6%
14 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • ChemoMetec has fallen 7.4% over the past year, including dividends.
  • Overall, ChemoMetec ranks better than 72% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 74.4%. The price is 35.6% below its peak now.

What do analysts think of ChemoMetec?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

72

Quality, value and trend together. Better than 72% of Nordic stocks.

No. 35 of 195 in healthcare

Quality100
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 1 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.01
  • Asset turnoverSales divided by everything the company owns0.59
  • Return on equityProfit divided by equity+27.8%
  • Cash conversionOperating cash flow divided by profit1.04

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value6
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 159 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity16.0
  • P/SPrice divided by sales22.7
  • P/EPrice divided by earnings57.5
  • P/CFPrice divided by operating cash flow55.2

The ranking is built on P/E, P/B and P/S.

Trend81
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 40 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+42.5%
  • 6 months+106.6%
  • 9 months+72.7%
  • 12 months−7.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+20.6%
3 years, per year
+26.5%
5 years, per year
−7.1%
10 years, per year
+35.8%
Largest fall, 3 years
−74.4%
From a peak to the bottom
From the peak now
−35.6%
How far the price is from the peak
Volatility, 1 year
64.0%
How much the price swings over a year
Beta, 1 year
1.02
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own ChemoMetec

15 funds we follow own ChemoMetec. The share is how much of the fund the stock makes up.

  • Norway2
  • Sweden9
  • Denmark4

From the funds' latest known holdings.

About ChemoMetec

ChemoMetec A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 170 employees.

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer.

See the full analysis of ChemoMetec.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market